Resources
15 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/26/2023 (updated 3/26/2024)
This presentation included an overview of the Moms Do Care EMPOWER (Engaging Mothers for Positive Outcomes with Early Referrals) program at Baystate Franklin Medical Center (BFMC). We discussed our history and program model.
Posted 3/15/2022 (updated 3/27/2024)
Pre- Pregnancy fact sheet. Information for Providers
Posted 5/12/2023 (updated 3/27/2024)
The Policy Center for Maternal Mental Health, in collaboration with the George Washington University, released the first-ever grading of state efforts in addressing maternal mental health. The U.S. received a D, and 42 states received Ds and Fs.
Posted 12/8/2023 (updated 3/28/2024)
This fact sheet from the Policy Center for Maternal Mental Health about AI/AN Maternal Mental Health provides information on the disparities American Indian and Alaskan Native (AI/AN) women experience including Maternal Death, Trauma: A Contributing Factor to Post-traumatic Stress Disorder (PTSD), Intimate Partner Violence (IPV), and Inequities and Systemic Racism Lead to Stress and Adverse Outcomes.
Posted 5/27/2020 (updated 3/28/2024)
Please see attached technical modules to help guide you as you work to address the opioid epidemic in your communities. They are a resource for you to identify best practices and implementation models for prevention, treatment, and recovery.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 9/1/2021 (updated 4/2/2024)
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.